LncRNA Information
ID EL0325 Name CYTOR Aliases C2orf59; LINC00152; NCRNA00152
Species Homo sapiens Chromosome 2 Start site 87455368
End site 87606805 Chain plus Exon NO. 5
Assembly Ensembl Release 89 Class lincRNA NCBI accession NR_024205, NR_024206, NR_024204
Ensembl ENSG00000222041 Sequence


Disease
Disease Method Sample Expression pattern Dysfunction type Description PMID Source
gastric cancer microarray, qPCR, Western blot, knockdown etc. gastric cancer tissue, cell lines (HCG-27, SGC-7901) up-regulated expression Linc00152 was validated to be increased in 59 paired gastric cancer specimens (Fig. 3C), and the high levels of Linc00152 expression correlated with larger tumor size. 26237576 Lnc2Cancer
hepatocelluar carcinoma microarray, qPCR, Western blot, Luciferase reporter assay etc. HCC tissue, cell lines ( HepG2, Hep3B, SNU-423 cells. Huh7, L02, SMMC-7721, MHCC-97H) up-regulated interaction Here, based on the increased level of LINC00152 in HCC tissues, we found that LINC00152 could promote cell proliferation in vitro and tumor growth in vivo. Furthermore, microarray-based analysis indicated that LINC00152 could activate the mechanistic target of rapamycin(mTOR) pathway by binding to the promoter of EpCAM through a cis-regulation, as confirmed by Gal4-N/BoxB reporter system. 26540343 Lnc2Cancer
gastric cancer qPCR etc. blood(serum) up-regulated expression The levels of plasma LINC00152 were significantly elevated in gastric cancer patients compared with healthy controls. The sensitivity and specificity of plasma LINC00152 in the diagnosis of gastric cancer were 48.1 and 85.2 %, respetcively. LINC00152 levels in preoperative plasma samples were lower than those in postoperative ones. 25391424 Lnc2Cancer
hepatocelluar carcinoma qPCR etc. blood (plasma), HCC tissue up-regulated expression Circulating HULC and Linc00152 were significantly up-regulated in plasma samples of HCC patients during training set and validation set. 26356260 Lnc2Cancer
gastric cancer qPCR, Western blot, ISH, RIP, RNA pull-down assay etc. gastric cancer tissue, cell lines (MGC803, HGC-27) up-regulated interaction In this study, we first confirmed the upregulation of cytoplasmic expressed Linc00152 in 72 pair tissues of gastric patients. A suppression of cell proliferation and tumor growth was obtained in MGC803 and HGC-27 cells treated with Linc00152 shRNA. RNA pull-down and RIP assay revealed that Linc00152 could directly bind with EGFR which caused an activation of PI3K/AKT signaling. 26538117 Lnc2Cancer
pancreatic cancer qPCR, Western blot, knockdown etc. PDAC tissue up-regulated expression The upregulation of LINC00152 (MACE log2fc: 2.3, qPCR: 1.5) and downregulation of LINC00261 (MACE log2fc: 5.3, qPCR: 4.4) in PDAC tissues was confirmed by qPCR. 25910082 Lnc2Cancer
gastric cancer qPCR, Western blot, Northern blot, knockdown etc. gastric cancer tissue, cell lines (AGS, BGC-823, MGC-803, SGC-7901 etc.) up-regulated N/A The results showed that the expression level of LINC00152 in gastric carcinoma was significantly increased, compared with matched normal tissue (P=0.045) and normal mucosa from health control (P=0.004), respectively. Levels of LINC00152 in gastric cancer cell lines, BGC-823, MGC-803, and SGC-7901, were significantly higher than those in human normal gastric epithelial cell line GES-1. In addition, high expression of LINC00152 was correlated with invasion (P=0.042). LINC00152 levels in gastric juice from patients with gastric cancer were further found significantly higher than those from normal controls (P=0.002). 24523021 Lnc2Cancer
 


Interaction
Interaction target Level of interaction Type of interaction Description PMID Source
EGFR RNA-Protein binding Linc00152 could directly bind with EGFR which caused an activation of PI3K/AKT signaling. 26538117
EpCAM RNA-DNA binding LINC00152 could activate the mechanistic target of rapamycin(mTOR) pathway by binding to the promoter of EpCAM through a cis-regulation, as confirmed by Gal4-λN/BoxB reporter system. 26540343